New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
05:46 EDTARIA, GSK, LLY, JAZZ, SHPGRumors suggest Jazz looking to buy ARIAD, Daily Mail reports
Rumors suggest that Jazz Pharmaceuticals (JAZZ) is willing to pay $20-plus per share to acquire ARIAD (ARIA), Daily Mail says in its Market Report. GlaxoSmithKline (GSK), Shire (SHPG) and Eli Lilly (LLY) are rumored to have lost out on the auction for ARIAD, the paper adds. Reference Link
News For ARIA;JAZZ;GSK;SHPG;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 28, 2015
09:24 EDTSHPG, JAZZJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
09:00 EDTSHPGPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
08:35 EDTLLYEli Lilly reports final results of Phase III trial for Alimta
Eli Lilly announced final results of the Phase III PROCLAIM trial, a randomized, Phase III superiority study of patients with locally-advanced, nonsquamous non-small cell lung cancer, which evaluated Lilly's Alimta in combination with cisplatin with concurrent radiation followed by maintenance Alimta in comparison with etoposide and cisplatin plus concurrent radiation, followed by consolidation chemotherapy of the oncologist's choice. Those treated on the pemetrexed arm achieved a median overall survival of 26.8 months as compared to 25 months for those treated on the etoposide arm. Median progression-free survival was 11.4 months on the pemetrexed arm versus 9.8 months on the etoposide arm and an overall response rate of 35.9% on the pemetrexed arm and 33% on the etoposide arm.
08:09 EDTLLYEli Lilly to present data from several trials of Cyramza for cancer
Subscribe for More Information
07:25 EDTSHPGEuro Renal Association / Euro Dialysis & Transplant Assoc to hold conference
52nd ERA-EDTA Congress is being held in London, England on May 28-31.
May 27, 2015
18:18 EDTJAZZRosewind acquires ProstaScint assets from Jazz Pharmaceuticals
In a regulatory filing earlier, Ampio Pharmaceuticals (AMPE) reported that on May 20, Rosewind, an approximately 81.5%-owned subsidiary of Ampio, entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals (JAZZ). Pursuant to the agreement, Rosewind purchased assets related to ProstaScint, or capromab pendetide, including certain intellectual property and contracts, and the product approvals, inventory and work in progress, and assumed certain of Jazz's liabilities, including those related to product approvals and the sale and marketing of ProstaScint. Rosewind paid $1M at closing for the ProstaScint assets. Rosewind has also agreed to pay an additional $500,000 within five days after transfer for the ProstaScint-related product inventory, and $226,523 payable on September 30, which represents a portion of certain United States Food and Drug Administration fees. Rosewind also will pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of $2.5M. The agreement also provides that for a period of one year, Jazz agrees to not directly or indirectly, through any of its agents or affiliates, compete against ProstaScint, or acquire a company or business in which more than 15% of such acquired business’ total revenue is generated by products that compete with ProstaScint.
08:32 EDTLLYEli Lilly's Humalog KwikPen approved by FDA
Subscribe for More Information
May 26, 2015
08:14 EDTSHPG, GSKBoston Biotech Conferences to hold a conference
Subscribe for More Information
May 22, 2015
10:52 EDTGSK, LLYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:37 EDTARIAARIAD announces data presentations at EHA Congress
Subscribe for More Information
May 21, 2015
07:37 EDTSHPG, LLY, GSKPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
10:29 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
08:12 EDTJAZZJazz Pharmaceuticals management to meet with Leerink
Subscribe for More Information
07:46 EDTGSKDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
07:21 EDTJAZZUBS to hold a conference
Subscribe for More Information
May 19, 2015
11:59 EDTARIAOptions with decreasing implied volatilit
Subscribe for More Information
09:25 EDTGSKGlaxoSmithKline asthma drug overused, risks underappreciated, ProPublica says
Subscribe for More Information
06:55 EDTGSKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
12:24 EDTJAZZJazz Pharmaceuticals management to meet with Guggenheim
Subscribe for More Information
10:37 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use